Yingsheng Biology Completed Around $14 Million in Series C Financing

On June 4, 2019, Domestic mass spectrometry company Yingsheng Biology has completed around 14 million dollars in Series C financing. This round of financing was led by Bio Venture and followed by Xiamen C&D Inc.  

YIngsheng Biology was founded back in 2009 in Jinan, China. The company has always been researching, developing, producing and selling the In vitro diagnostic reagents and medical devices, and building a genetic testing platform and a mass spectrometry detection platform around genomics and mass spectrometry. Yingsheng Biology’s product also includes 45 innovative genetic metabolic screening agents for newborns.

Mr. Zhen Feng, Chairman of Yingsheng Biology, said “ Yingsheng’s one-step solution for mass spectrometry will make mass spectrometry the most commonly used inspection method in hospitals. The goal of Yingsheng Biology is to make mass spectrometry a simple, convenient, fast, accurate and affordable means of detection. Yingsheng also cooperates with the global scientific instrument giant ThermoFisher to localize production of high-end mass spectrometers such as LC-MS and ICP-MS, reducing the price of mass spectrometers”.

Bioventure its first element of the new bio-industry funds 540 million RMB fund size. Bioventure specializes in the field of life sciences in the early stages of venture capital investments.

Xiamen C&D Inc was set up in Dec 1980, and it is a large-scale industrial & investment enterprise group in Fujian Province with a registered capital of 5 billion RMB, a total asset of over 150 billion RMB, and an annual operation revenue of over 147 billion RMB.